Read + Share
Lawrence L. Novel therapies create potential new options for patients with advanced breast
cancer: First-line sacituzumab govitecan plus pembrolizumab may improve long-term
outcomes for patients with advanced triple-negative breast cancer, whereas the
new CDK4/6 Cancer 2026;132:e70619.
PMID: 42973392
|
 |
|
